T2 Biosystems, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-03-24: Reporting owner Gibbs Michael Terrence; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-03-14: Reporting owner Barclay Alec; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-03-14: Reporting owner Lowery Thomas J.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-03-14: Reporting owner Pare Anthony; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-03-24 | Gibbs Michael Terrence Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.39 exercise price | 2020-03-26 | |
| 2020-03-14 | Barclay Alec Officer (SVP, Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 130,000 owned after | $0.40 exercise price | 2020-03-18 | |
| 2020-03-14 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +180,000 180,000 owned after | $0.40 exercise price | 2020-03-18 | |
| 2020-03-14 | Pare Anthony Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,000 105,000 owned after | $0.40 exercise price | 2020-03-18 | |
| 2020-01-29 holding as of filing | Pare Anthony Officer (Chief Commercial Officer) | 3 | Stock Option Derivative · Direct | Holding | $3.10 exercise price | 2020-01-29 | ||
| 2020-01-29 holding as of filing | Pare Anthony Officer (Chief Commercial Officer) | 3 | Stock Option Derivative · Direct | Holding | $1.43 exercise price | 2020-01-29 | ||
| 2020-01-29 holding as of filing | Pare Anthony Officer (Chief Commercial Officer) | 3 | Stock Option Derivative · Direct | Holding | $1.15 exercise price | 2020-01-29 | ||
| 2020-01-14 holding as of filing | Sperzel John J III Director, Officer (See Remarks) | 3 | Stock Option Derivative · Direct | Holding | $1.15 exercise price | 2020-01-14 | ||
| 2020-01-06 holding as of filing | GOLDMAN SACHS GROUP INC | GOLDMAN SACHS & CO. LLC 10% Owner | 10% Owner | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 66,176 owned after | $8.92 exercise price | 2020-01-06 | |
| 2020-01-06 holding as of filing | GOLDMAN SACHS GROUP INC | GOLDMAN SACHS & CO. LLC 10% Owner | 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 22,000 owned after | $1.54 exercise price | 2020-01-06 | |
| 2020-01-06 holding as of filing | Jones Adrian M Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 66,176 owned after | $8.92 exercise price | 2020-01-06 | |
| 2020-01-06 holding as of filing | Jones Adrian M Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 22,000 owned after | $1.54 exercise price | 2020-01-06 |